ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the ABSTRACT TEMPLATE online, for Biomed 2026 Company Presentations

All items marked with an * are mandatory to complete

The maximum number of words for this abstract is 400

Please be sure to complete the following:

Company name-------Insitro------- * Website----------https://www.insitro.com/*

Site Lead name--------Noam Katz

Select a CATEGORY: Biotech/Pharma

(Delete categories you are not selecting)

Select one SESSION per abstract from the list below *

(Delete sessions you are not selecting)

"AI Pharma" drug discovery, Quantum Computing."

You may delete the section instructions, leaving only the bolded bullet title
Answers below should not exceed 60 words per question:

- Executive Summary / Investment Rational: Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

Title: Bridging Platforms: The Strategic Integration of CombinAble and insitro in AI-Driven Biologics Discovery

Drug discovery is increasingly becoming a data problem, but not in the abstract sense. The real challenge is generating the right biological data, at the right scale, and building models that can turn that data into better therapeutic decisions. This talk will describe the strategic and scientific rationale behind the acquisition of CombinAble by insitro, and why the fit between the two companies is especially meaningful for the future of AI-enabled biologics discovery.

CombinAble was founded to address a central bottleneck in antibody discovery: the difficulty of optimizing many therapeutic properties at once. Finding a binder is no longer enough. A successful antibody must combine potency, specificity, developability, manufacturability, and ideally a path toward differentiated biology. CombinAble's platform was built around high-throughput experimental screening and machine learning models that can learn from large antibody datasets and guide the design of improved candidates across multiple objectives.

insitro brings a highly complementary foundation: a platform that integrates large-scale biology, disease-relevant cellular systems, human genetics, automation, and machine learning to better understand disease and discover medicines. The acquisition creates a natural connection between disease biology and biologics engineering. In practical terms, it strengthens the ability to move from understanding a disease mechanism, to identifying the right therapeutic hypothesis, to designing and optimizing biologic molecules that can act on that hypothesis.

The talk will cover the investment and strategic rationale behind the acquisition, the uniqueness of CombinAble's antibody engineering capabilities, and how they fit within insitro's broader mission. It will also discuss how platform companies can create value not only through individual programs, but through repeatable engines that improve over time as more data is generated.

Finally, the talk will reflect on what this integration means for the broader field: the shift from traditional, sequential discovery workflows toward more iterative systems where experimental data and machine learning continuously inform each other. The goal is not to replace biology with algorithms, but to build a tighter loop between biology, computation, and therapeutic execution - one that can make drug discovery faster, more predictive, and ultimately more successful.